Cancer immunity mainly relies on CD8+ cytotoxic T lymphocytes (CTLs); tumor-specific CTLs proliferate and are directed to tumor sites, where they attack cancer cells due to professional APC (pAPC) cross-priming of naive CD8+ T cells [129]. The gene discussed is CD8A; the disease is cancer.